Tag: POLARIX study
Polatuzumab Vedotin Demonstrates Clinical Efficacy Across a Range of Diffuse Large...
Polatuzumab vedotin (DCDS4501A), a novel, targeted anti-cancer agent being developed by Genentech/Roche, is a first-in-class anti-CD79b antibody-drug conjugate or ADC currently being investigated for...